These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 10905585

  • 21. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
    Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.
    Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
    [Abstract] [Full Text] [Related]

  • 22. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome.
    Kim HR, Lee YS, Yim HJ, Lee HJ, Ryu JY, Lee HJ, Yoon EL, Lee SJ, Hyun JJ, Jung SW, Koo JS, Choung RS, Lee SW, Choi JH.
    Clin Mol Hepatol; 2013 Dec; 19(4):417-20. PubMed ID: 24459647
    [Abstract] [Full Text] [Related]

  • 23. Terlipressin in the treatment of hepatorenal syndrome: A systematic review and meta-analysis.
    Wang H, Liu A, Bo W, Feng X, Hu Y.
    Medicine (Baltimore); 2018 Apr; 97(16):e0431. PubMed ID: 29668606
    [Abstract] [Full Text] [Related]

  • 24. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
    Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O.
    Acta Gastroenterol Belg; 2001 Apr; 64(1):15-9. PubMed ID: 11322061
    [Abstract] [Full Text] [Related]

  • 25. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics.
    Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber P, Terlipressin Study Group.
    J Hepatol; 2011 Aug; 55(2):315-21. PubMed ID: 21167235
    [Abstract] [Full Text] [Related]

  • 26. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
    Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, Balzola F, Morgando A, Rizzetto M, Marzano A.
    J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
    [Abstract] [Full Text] [Related]

  • 27. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
    Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK.
    J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
    [Abstract] [Full Text] [Related]

  • 28. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
    Caraceni P, Santi L, Mirici F, Montanari G, Bevilacqua V, Pinna AD, Bernardi M.
    Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
    [Abstract] [Full Text] [Related]

  • 29. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
    Ganne-Carrié N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP.
    Dig Dis Sci; 1996 Jun; 41(6):1054-6. PubMed ID: 8654133
    [Abstract] [Full Text] [Related]

  • 30. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.
    Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, Binn M, Grangé JD, Valla D, Lebrec D.
    Gut; 2002 Jan; 50(1):90-4. PubMed ID: 11772973
    [Abstract] [Full Text] [Related]

  • 31. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
    Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, Kidokoro H, Harimoto H, Fukuda T, Matsushita Y, Nakatsuka K, Sakamoto C.
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
    [Abstract] [Full Text] [Related]

  • 32. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
    Gifford FJ, Morling JR, Fallowfield JA.
    Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
    [Abstract] [Full Text] [Related]

  • 33. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
    Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, Arroyo V, Rodés J.
    Hepatology; 1998 Jan; 27(1):35-41. PubMed ID: 9425914
    [Abstract] [Full Text] [Related]

  • 34. Terlipressin for hepatorenal syndrome.
    Gluud LL, Christensen K, Christensen E, Krag A.
    Cochrane Database Syst Rev; 2012 Sep 12; (9):CD005162. PubMed ID: 22972083
    [Abstract] [Full Text] [Related]

  • 35. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
    Wong F, Pappas SC, Boyer TD, Sanyal AJ, Bajaj JS, Escalante S, Jamil K, REVERSE Investigators.
    Clin Gastroenterol Hepatol; 2017 Feb 12; 15(2):266-272.e1. PubMed ID: 27464593
    [Abstract] [Full Text] [Related]

  • 36. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
    Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M.
    Eur J Gastroenterol Hepatol; 2002 Dec 12; 14(12):1363-8. PubMed ID: 12468959
    [Abstract] [Full Text] [Related]

  • 37. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK.
    Eur J Gastroenterol Hepatol; 2010 Apr 12; 22(4):481-6. PubMed ID: 19952764
    [Abstract] [Full Text] [Related]

  • 38. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
    Fabrizi F, Dixit V, Messa P, Martin P.
    Int J Artif Organs; 2009 Mar 12; 32(3):133-40. PubMed ID: 19440988
    [Abstract] [Full Text] [Related]

  • 39. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
    Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A.
    Dig Liver Dis; 2009 Apr 12; 41(4):298-302. PubMed ID: 19158001
    [Abstract] [Full Text] [Related]

  • 40. Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature.
    Kalil JR, Cerqueira LA, Barbosa DS, Motta MP, Nery Mda S, Bittencourt PL.
    Arq Gastroenterol; 2009 Apr 12; 46(3):214-8. PubMed ID: 19918689
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.